1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJohns, Michael S.-
dc.contributor.authorMerritt, William T.-
dc.contributor.authorRhodes, Lori-
dc.contributor.authorFord, Candice N.-
dc.contributor.authorThompson, Mark-
dc.contributor.authorLee, William M.-
dc.contributor.authorSheldon, Yarrow-
dc.contributor.authorPetrelli, Nicholas J.-
dc.contributor.authorTiesi, Gregory J.-
dc.date.accessioned2022-05-06T08:28:46Z-
dc.date.available2022-05-06T08:28:46Z-
dc.date.issued2022-02-03-
dc.identifier.issn1078-1552de_CH
dc.identifier.issn1477-092Xde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/24912-
dc.description.abstractIntroduction: A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment. Utilizing these trial data, we performed a cost analysis of sorafenib efficacy through two years of treatment. Methods: Current Medicare Part D rates for sorafenib were utilized (dose 400 mg/day, cost $309/day). Annual costs per progression and objective response were calculated. Radiologic progression and response were defined using RECIST criteria. Patients with disease progression were separately analyzed in two groups: both clinical and radiologic (CAR), and radiologic alone. Results: 84 previously randomized patients were analyzed (placebo: 35, sorafenib: 49). At one year, sorafenib was associated with a 43% absolute risk reduction (ARR) of CAR progression and number-needed-to-treat (NNT) of 2.3 patients/year, costing $259,406. At two years, ARR was 48% and NNT of 2.1 patients/year, costing $473,697. When evaluating only patients with RECIST defined radiologic progression, sorafenib patients experienced ARR of 13.9% with NNT 7.2 and estimated costs of $812,052 at one year. Two-year ARR was 17.5% with NNT 5.7 and estimated costs $1,285,052. Sorafenib patients experienced improved RECIST partial response rates at 1 and 2 years of 14.7% and 14.3%, with NNT 6.8 and 6.9, and costs of $766,938 and $1,556,433; respectively. Conclusion: For the treatment of desmoid tumors, Sorafenib led to improved PFS, but at a significant cost per patient. Favorable RECIST outcomes were less likely and costlier. Patients should be informed of possible benefits of treatment versus potential financial burden.de_CH
dc.language.isoende_CH
dc.publisherSagede_CH
dc.relation.ispartofJournal of Oncology Pharmacy Practicede_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectDesmoid tumorde_CH
dc.subjectCost analysisde_CH
dc.subjectOncologyde_CH
dc.subjectSorafenibde_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.subject.ddc616: Innere Medizin und Krankheitende_CH
dc.titleA cost analysis of sorafenib for desmoid tumorsde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitInstitut für Wealth & Asset Management (IWA)de_CH
dc.identifier.doi10.1177/10781552221077927de_CH
dc.identifier.pmid35112974de_CH
zhaw.funding.euNode_CH
zhaw.issue3de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end668de_CH
zhaw.pages.start663de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume29de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.
Show simple item record
Johns, M. S., Merritt, W. T., Rhodes, L., Ford, C. N., Thompson, M., Lee, W. M., Sheldon, Y., Petrelli, N. J., & Tiesi, G. J. (2022). A cost analysis of sorafenib for desmoid tumors. Journal of Oncology Pharmacy Practice, 29(3), 663–668. https://doi.org/10.1177/10781552221077927
Johns, M.S. et al. (2022) ‘A cost analysis of sorafenib for desmoid tumors’, Journal of Oncology Pharmacy Practice, 29(3), pp. 663–668. Available at: https://doi.org/10.1177/10781552221077927.
M. S. Johns et al., “A cost analysis of sorafenib for desmoid tumors,” Journal of Oncology Pharmacy Practice, vol. 29, no. 3, pp. 663–668, Feb. 2022, doi: 10.1177/10781552221077927.
JOHNS, Michael S., William T. MERRITT, Lori RHODES, Candice N. FORD, Mark THOMPSON, William M. LEE, Yarrow SHELDON, Nicholas J. PETRELLI und Gregory J. TIESI, 2022. A cost analysis of sorafenib for desmoid tumors. Journal of Oncology Pharmacy Practice. 3 Februar 2022. Bd. 29, Nr. 3, S. 663–668. DOI 10.1177/10781552221077927
Johns, Michael S., William T. Merritt, Lori Rhodes, Candice N. Ford, Mark Thompson, William M. Lee, Yarrow Sheldon, Nicholas J. Petrelli, and Gregory J. Tiesi. 2022. “A Cost Analysis of Sorafenib for Desmoid Tumors.” Journal of Oncology Pharmacy Practice 29 (3): 663–68. https://doi.org/10.1177/10781552221077927.
Johns, Michael S., et al. “A Cost Analysis of Sorafenib for Desmoid Tumors.” Journal of Oncology Pharmacy Practice, vol. 29, no. 3, Feb. 2022, pp. 663–68, https://doi.org/10.1177/10781552221077927.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.